Welcome to our dedicated page for Pharmacyte Biotech SEC filings (Ticker: PMCB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Pharmacyte Biotech’s Cell-in-a-Box capsules may one day localize chemotherapy inside a pancreatic tumor or replace daily insulin injections, but the science that excites clinicians can overwhelm investors. Clinical timelines, R&D spend, and dilution risk hide in pages of dense disclosures. That’s why the most common Google questions—“Where are Pharmacyte Biotech insider trading Form 4 transactions?” and “How do I read a Pharmacyte Biotech quarterly earnings report 10-Q filing?”—keep surfacing.
Stock Titan’s platform turns that struggle into clarity. Our AI reads every sentence as soon as it hits EDGAR, delivering Pharmacyte Biotech Form 4 insider transactions real-time, cash-flow highlights from the latest 10-Q, and side-by-side comparisons of trial milestones. The result: Pharmacyte Biotech SEC filings explained simply without sacrificing rigor. Each document arrives with concise takeaways, risk flags, and links to the exact page so you can move from high-level Pharmacyte Biotech earnings report filing analysis to original text in a click.
Need deeper context? Use our guided navigator to jump from a Pharmacyte Biotech annual report 10-K simplified to the section on Cell-in-a-Box intellectual property, or scan a Pharmacyte Biotech proxy statement executive compensation table before voting. Real-time alerts cover every Pharmacyte Biotech 8-K material events explained, ensuring trial suspensions, licensing deals, or capital raises never slip past. Whether you’re tracking Pharmacyte Biotech executive stock transactions Form 4 or understanding Pharmacyte Biotech SEC documents with AI, Stock Titan provides the full picture—complete, current, and instantly actionable.
PharmaCyte Biotech (PMCB) reported shareholder approvals from its October 30, 2025 special meeting. Stockholders authorized, for purposes of complying with Nasdaq Listing Rule 5635(d), the issuance of shares of common stock underlying convertible preferred stock and warrants issued under the August 17, 2025 Securities Purchase Agreement and related placement engagement, in an amount equal to or in excess of 20% of common shares outstanding before those issuances, including any anti-dilution adjustments.
Shareholders also approved an amendment to the 2022 Equity Incentive Plan to increase the number of shares available for awards by 2,250,000 shares. Voting results: Proposal 1 passed with 1,649,395 for, 249,100 against, 47,316 abstaining; Proposal 2 passed with 2,348,827 for, 399,696 against, 118,421 abstaining; and adjournment authority (Proposal 3) passed with 2,496,898 for, 311,836 against, 58,210 abstaining. A quorum was present with 2,866,944 shares represented, approximately 37.1% of shares entitled to vote.
PharmaCyte Biotech, Inc. seeks shareholder approval at a special meeting for three principal items: an Issuance Proposal, a Plan Amendment Proposal to add 2,250,000 shares to its 2022 Equity Incentive Plan, and an Adjournment Proposal to postpone the meeting if there are insufficient votes or no quorum. The filing lists security ownership of management and certain large holders, including an affiliated group with
PharmaCyte Biotech, Inc. is soliciting votes at a virtual special meeting to consider several proposals including approval of an issuance proposal, an amendment to the 2022 Equity Incentive Plan to add 2,250,000 shares available for awards, and an adjournment proposal to permit additional solicitation if needed. The proxy materials include voting methods (by mail or during the virtual meeting) and a security ownership table showing entities affiliated with Intracoastal Capital LLC hold 714,844 shares (about 10.23%) and all directors and executive officers as a group hold 770,230 shares (about 10.33%), with Chairman/CEO Joshua N. Silverman shown with 220,000 shares (approximately 3.16%). The materials reference the full text of the amended Equity Incentive Plan in an appendix.
PharmaCyte Biotech, Inc. (PMCB) filed an S-3 shelf registration to register shares issuable upon conversion of Series C Preferred Stock and upon exercise of outstanding warrants and placement agent warrants. The prospectus notes the company would receive up to approximately $7.5 million only if all warrants are exercised for cash; otherwise selling stockholders will receive proceeds from secondary sales. The registration covers shares held by multiple institutional and individual selling stockholders (many pegged at 4.99% ownership thresholds) and includes a 150% sizing convention used to calculate maximum conversion and warrant share counts. The document reiterates significant risks including a clinical hold interaction with the FDA on an IND for a planned LAPC clinical trial, long drug-development timelines, dependence on third parties, potential illiquidity, and general regulatory and competitive risks. The offering may enable secondary liquidity but also creates potential dilution if conversions/exercises occur.
FAQ
What is the current stock price of Pharmacyte Biotech (PMCB)?
What is the market cap of Pharmacyte Biotech (PMCB)?
